Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
Express Scripts
McKinsey
Moodys

Last Updated: December 7, 2022

Details for Patent: 8,592,362


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,592,362
Title:Method to predict response to pharmacological chaperone treatment of diseases
Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining .alpha.-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of .alpha.-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.
Inventor(s): Benjamin; Elfrida (Millstone Township, NJ), Do; Hung V. (New Hope, PA), Wu; Xiaoyang (Edison, NJ), Flanagan; John (East Windsor, NJ), Wustman; Brandon (San Diego, CA)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:12/855,468
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,592,362
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,592,362

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Therap Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y THE TREATMENT OF FABRY PATIENTS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,592,362

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 111971 See Plans and Pricing
Australia 2009214648 See Plans and Pricing
Australia 2014221321 See Plans and Pricing
Australia 2016206297 See Plans and Pricing
Australia 2017268649 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
McKesson
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.